Theragenics Corp said it will receive a
U.S. patent on its TheraSeed localized radiation therapy for
treatment of prostate cancer, effective June 23.
    It said it has obtained product liability insurance for
Theraseed and expects commercial sales and distribution to
start by July 15.
 Reuter
&#3;